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Rationale:  Previous studies have suggested that antihistamines may be therapeutic in some 
patients with asthma.  Variation in genes along the histamine production, response, and 
degradation pathway may be important in predicting response to antihistamines. We hypothesize 
that genetic variation in genes of the histamine pathway differs between children with allergic 
versus non-allergic asthma.  
Methods:  Children 7-18 years of age (n=118) with asthma participated in this IRB-approved 
protocol and were classified as allergic (N = 68) or non-allergic (N = 50) based on allergy skin 
testing. DNA isolation and genotyping were performed for 10 SNPs within 4 genes (HDC, 
HNMT, ABP1, HRH1, HRH4) within the histamine pathway. Chi Square tests were used to test 
for associations between genotypes and allergic or non-allergic asthma among participants. 
Significance was determined by p <0.05.     
Results:  We observed differences in genotype frequency between participants with allergic 
versus non-allergic asthma for 2 SNPs: HNMT-1639(rs6430764) (31% allergic with TT vs. 14% 
non-allergic with TT, p=0.04) and HNMT -464 (rs2071048)  genotype (33% allergic with TT vs. 
12% non-allergic with TT, p=0.03) after controlling for race. Differences in genotype frequency 
were also observed between allergic and non-allergic phenotypes in stratified analyses among 
African Americans.  
Conclusion:  Genetic variants within the histamine pathway appear to be associated with an 
allergic versus non-allergic asthma phenotype. Further studies are needed to validate our findings 
in a larger cohort. There is also the need to determine the functional significance of identified 






I would like to acknowledge my committee members J. Steven Leeder, Lanny J. Rosenwasser, 
and Brooke L. Fridley for their guidance during conduct of this work and my thesis 
development. I would also like to acknowledge the work of my colleagues and collaborators 
Carrie A. Vyhlidal, PhD, Sara Anvari, MD, Mohammad Rezaiekhaligh, and Honging Dai, PhD. 
Finally, support was provided for this work by funds from the National Heart, Lung, and Blood 






TABLE OF CONTENTS 
Abstract     iii 
Acknowledgments    iv 
Introduction     1 
Materials and Methods   4 
Results     6 
Discussion     11 






Asthma is a chronic inflammatory disease characterized by airway hyper-responsiveness, 
airflow obstruction and variable reversibility in response to various exposures. According to the 
CDC’s National Asthma Surveillance Report, since 2001 the prevalence of asthma has increased 
by 2.9% each year from 20.3 million persons in 2001 to 25.7 million persons in 2010 [1].  
Asthma is also one of the most common chronic childhood diseases in developed countries; and 
according to the 2012 National Health Interview Survey, more than 7.1 million children had an 
asthma diagnosis in 2011 [1].    
 Asthma is a complex disease whereby the underlying pathophysiology is not completely 
understood.  Several phenotypes of asthma have been identified based on underlying 
inflammatory mediators or triggers [2].  Allergic and non-allergic asthma are common 
phenotypic classifications among patients with asthma.  Allergic asthma is defined as asthma 
with allergen hypersensitivity while non-allergic asthma is defined as asthma without allergen 
hypersensitivity. It is reported that up to 80% of asthma patients classify as allergic asthma[3].  
Non-allergic asthma includes a diverse group of described phenotypes such as infection induced 
asthma, pre-asthma wheezing, eosinophilic asthma, neutrophilic asthma, paucigranulocytic 
asthma, aspirin sensitive asthma, exercise induced bronchospasm, severe asthma, and flare prone 
asthma [4].   Better understanding of the underlying pathophysiology of differing asthma 
phenotypes is important in improving disease evaluation and management.    
Histamine (2-[4-imidazole] ethylamine) is a biogenic amine and a known mediator in the 
pathogenesis of allergic rhinitis and asthma [5, 6].  In the lungs, histamine receptor activation 
results in bronchospasm and airway obstruction. Plasma histamine levels have been found 




vascular permeability, mucus production, and contraction of airway smooth muscle cell [9-12]. 
Histamine also has an important immunoregulatory role as it affects T cell-helper type I and II 
responses.  The amine also directly participates in the functions and activity of dendritic cells 
[13].   
Targeting histamine as a therapeutic treatment has also shown benefit among some 
patients with asthma.  The use of type 1-receptor antihistamines (H1 antihistamines) has been 
shown to reduce respiratory symptoms and need for rescue medications in children with allergic 
asthma [14].  Furthermore, the use of antihistamines in atopic children and children considered 
high-risk for atopy appeared to prevent the onset of asthma when compared with placebo [15, 
16].  These data suggest that histamine plays an important role in disease pathogenesis of asthma 
and the therapeutic response to asthma treatments, especially among targeted asthma phenotypes 
such as allergic asthma. It is important for us to learn more about the role of histamine in the 
body in relation to inflammatory diseases such as asthma so as to use this knowledge to improve 
therapeutic outcomes in diseases that involve histamine.      
 The synthesis of histamine begins with the alpha-decarboxylation of L-histidine by the 
enzyme histadine decarboxylase (HDC) [6, 17].  Histamine exerts its effects by activating 
histamine receptors on various cells throughout the body.  There are four known subtypes of 
histamine receptors (HR): HR1, HR2, HR3, and HR4.   HR1 is expressed on several cell types 
including airway and vascular smooth muscle cells, hepatocytes, chrondrocytes, nerve cells, 
endothelial cells, dendritic cells, monocytes, lymphocytes, eosinophils, neutrophils. Activation of 
the HR1 receptor leads to vasodilatation, erythema, increased vascular permeability, edema, and 
bronchoconstriction  [9, 18, 19].  The receptor is responsible for allergic responses such as 




types such as gastric parietal cells, smooth muscle cells, neurons, neutrophils, monocytes, 
macrophages, dendritic cells, lymphocytes, endothelial cells, and epithelial cells [10].  Activation 
of HR2 is commonly known to increase gastric acid secretion. However, it also is involved in 
smooth muscle relaxation, airway mucus production, and inhibition of histamine release from 
basophils and mast cells [19-21].  HR3 is expressed in the central and peripheral nervous system 
as a presynaptic receptor controlling the release of histamine and neurotransmitters in the human 
brain [10, 19, 22-24].  The HR3 receptor has been linked to satiety, sleep, and cognition [10, 25, 
26].  HR4 is expressed in the bone marrow, and peripheral blood hematopoietic cells such as 
neutrophils, eosinophils, monocytes, and T cells [27].  It is also expressed on both basophils and 
mast cells [28].  HR4 has a role in autoimmune and allergic conditions and is involved in cellular 
chemotaxis and inflammatory mediator release [10, 19].  Recent evidence also suggests that the 
receptor may play a significant role in histamine induced pruritus [29, 30].  HR4 inverse agonists 
have been shown to attenuate itch both in animal and human studies [31, 32].  
 Histamine is degraded by two major enzymes, Histamine N-methyltransferase (HNMT) and 
Diamine Oxidase (DAO), for subsequent removal from the body [6, 10].  HNMT is responsible 
for the majority of histamine degradation and is widely expressed in various tissues, including 
the bronchial epithelium, skin, ileum, and stomach [6, 10, 33, 34].  DAO is mainly involved in 
degradation of extracellular histamine and is expressed mainly in the colon and kidney [6, 10, 
35].  
The enzymes responsible for histamine production and degradation and receptors which mediate 
the effects of histamine may be important in diseases that involve the amine such as asthma. 
Variation has been observed among the genes coding for these proteins (HDC, H1R, H2R, H3R, 




unknown, several studies have been conducted to explore potential associations between 
histamine related genes and asthma and allergic disease [6, 17, 33-43]. We have previously 
reported that the HRH1 gene was more highly expressed in buccal tissue from those with asthma 
compared to those without asthma [44]. It is plausible that variation among genes involved in 
histamine production, response, and/or degradation may influence the disposition and effect of 
the amine within the body. Identification of genetic variants related to the pharmacology of 
histamine may be important to better understanding of the underlying pathophysiology of asthma 
sub-types in addition to predicting how asthma patients may respond to treatments that affect 
histamine (e.g. antihistamines). Therefore, we conducted a pilot investigation to identify 
differences in genetic variants along the histamine production, response and degradation pathway 
between children with allergic and non-allergic asthma. 
MATERIALS AND METHODS 
Study population 
All study participants were enrolled in an IRB-approved protocol after obtaining parental 
permission and, when appropriate (i.e. age ≥ 7), child assent. Convenience sampling was utilized 
for this clinic based case –control study.  Children with asthma were enrolled from Allergy, 
Asthma and Immunology outpatient clinics at Children’s Mercy in Kansas City, MO.  Children 
were then classified as non-allergic vs. allergic asthma.  Asthma was defined by ≥ 12% post-
bronchodilator reversibility in forced expiratory volume in 1 second (FEV1) or by an 
Allergy/Asthma specialist diagnosis based on clinical symptoms in children unable to perform 
spirometry.  The diagnosis of allergic rhinitis was determined by at least one positive skin prick 




seasonal or perennial allergen.  Subjects with non-allergic asthma were defined as children with 
negative skin prick test to regional seasonal and perennial allergens in the past year.  
DNA Extraction and Genotyping 
Five ml of blood was collected into a glass tube containing ACD or calcium EDTA 
anticoagulant, mixed by repeated inversion and either stored for up to 7 days at 4ºC or 
immediately frozen at -70ºC.  Genomic DNA was extracted from blood using the Illustra Blood 
Genomic Prep Mini Spin Kit (GE Healthcare, Piscataway, NJ).  Genotyping assays were 
performed on genomic DNA (12-16 ng) using commercially available TaqMan assays to detect 
the following SNPs of interest: rs10156191 (ABP1 47C/T),  rs10156191 (ABP1 4107 C/G), 
rs1049742 (ABP1 995C/T), rs17740607 (HDC 92C/T), rs901865 (HRH1 -17C/T), rs11665084 
(HRH4 413C/T), rs6430764 (HNMT -1639C/T), rs2071048 (HNMT 464C/T),  rs1050900 
(HNMT 3’UTRA/T), and rs11558538 (HNMT 314C/T) (Applied Biosystems, Foster City, CA) 
and KAPA Probe Fast qPCR master mix (Kapa Biosystems, Boston, MA).  SNPs were chosen 
based on their potential functional significance and previously investigated variants (rs11558538, 
rs10156191, rs10156191, rs901865), as well as those with an expected minor allele frequency 
(MAF) within our participant population (≥2%) among expected racial groups of African 
Americans and Caucasians [6, 33, 45, 46].  Genotyping was performed on an Eco TM Real-Time 
PCR System (Illumina, San Diego, CA) with a thermal profile of 95ºC for 3 minutes followed by 
40-50 cycles of 95ºC for 3 seconds and 64ºC for 20 seconds.  All samples were performed in 
duplicates to rule out random error.   
Statistical Analysis 
Concordance with Hardy-Weinberg equilibrium (HWE) was confirmed according to Chi Square 




calculator including analysis for ascertainment bias) [47]. HWE tests were completed by racial 
group   Statistical analyses were performed using SAS 9.2 (Cary, NC).  Chi-Square test and 
Student T-test was used to compare demographics between the allergic asthma and non-allergic 
asthma groups.  Fisher’s Exact tests (general genotypic model 2 degree of freedom test or co-
dominant genetic model) and Cochran-Armitage Trend tests (additive genetic model) were used 
to compare the genotype frequency  for each SNPs between asthmatic subjects with and without 
allergic sensitization. All analyses were completed by race followed by  Cochran-Mantel-
Haenszel (CMH) tests to compare the frequencies of genotype between allergic and non-allergic 
subjects, adjusted by the confounding race effect. Significance was determined by the nominal 
p<0.05 (not adjusting for testing of multiple SNPs). Adjustment for multiple testing with a 
Bonferroni correction would result in significance determined for p < 0.005 .   As exploratory 
analyses, we further evaluated genotype frequency according to the subgroup stratification of 
race.  
RESULTS 
  A total of 118 children between the ages of 7 through 18 years were included in this 
preliminary study. Participant demographics are shown in Table 1. Allergic asthma was more 
common among males and African Americans than non-allergic asthma (p<0.01 and 0.04 
respectively). Among African Americans allergic asthma was more frequent than non-allergic 






Table 1: Demographic characteristics of all participants and among those classified as allergic 
and non-allergic. 









Age in years: 
Mean±SD 
12.5 ± 3.3 12.7 ± 3.3 12.06 ± 3.2 0.80 
**Gender % (N):    0.008 
Males 54% (64) 69% (44) 31% (20) 
Females 46% (54) 44 %(24) 56 %(30) 
***Race % (N):    0.04 
†African 
American 
52% (61) 69% (42) 31% (19) 
Caucasian 38% (45) 44 %(20) 56% (25) 
Other 10% (12) 50% (6) 50% (6) 
** Increased frequency of those with allergic asthma compared to those with non-allergic asthma 
among males 
***Increased frequency of allergic asthma among African Americans 
†Allergic asthma was more frequent than non-allergic asthma among African Americans 
 
We observed differences in genotype frequency for 2 of the 10 SNPs evaluated between 
subjects with allergic and non-allergic asthma after correcting for the confounder of race.  The 
homozygous variant (TT) genotype for HNMT -464 (rs2071048) was more common among 
those with allergic asthma than those with non-allergic asthma (Table 2, TT=0.48 allergic 
asthma vs. TT=0.24 non-allergic asthma, p=0.03; Bonferroni corrected p value 0.3) (see Table 3 
for genotypes stratified by race).  The homozygous variant HNMT-1639 (rs6430764) genotype 
(TT) was also more common among allergic asthma participants than non-allergic asthma 
(Figure 2, TT=0.31 allergic vs. TT=0.14 non-allergic, p=0.04; Bonferroni corrected p-value 0.4) 
(see Table 3 for genotypes stratified by race). There were no significant differences observed for 












Genotype Allergic Asthma 













CC 1 (1) 4 (2) 0.62 
CT 12 (8) 14 (7) 





CC 57 (39) 72 (36) 0.09 
 
 
CT 35 (24) 28 (14) 
TT 
 





CC 93 (63) 92 (46) 0.84 
CT 7 (5) 8 (4) 
TT 
 





CC 19 (13) 18 (9) 0.04 
CT 50 (34) 68 (34) 
TT 
 
31 (21) 14 (7) 
rs2071048 
(C/T) 
CC 9 (6) 12 (6) 0.03 
CT 42 (29) 64 (32) 
TT 
 
49 (33) 24 (12) 
rs11558538 
(C/T) 
CC 90 (61) 78 (39) 0.63 
CT 9 (6) 20 (10) 
TT 
 
1 (1) 2 (1) 
rs1050900 
(A/T) 
AA 66 (45) 52 (26) 0.69 
AT 26 (18) 46 (23) 
TT 
 







CC 26 (18) 38 (19) 0.16 
CT 54 (37) 52 (26) 
TT 
 
19 (13) 10 (5) 
rs1049742 
(C/T) 
CC 79 (54) 86 (43) 0.56 
CT 21 (14) 12 (6) 
TT 
 
0 (0) 2 (1) 
rs1049793 
(C/G) 
CC 27 (18) 36 (18) 0.55  
CG 51 (35) 44 (22) 
GG 22 (15) 20 (10) 
*Major allele represents the most frequently-occurring allele; serves as reference for modeling. 
** P-values represented from Co-dominant genotype model from Cochran-Mantel-Haenszel test corrected 




Exploratory analysis among racial groups 
Genetic differences relative to race were observed. The HDC92 (rs17740607) TT 
genotype was more common among African Americans than Caucasians (TT=0.98 African 
American vs. 0.71 Caucasian, p<0.0001; Cochran-Armitage Trend p=0.0005).  There were no 
other differences in genotype frequencies observed between the racial groups.   
 Recognizing that disease phenotype and pathophysiology differ between different races 
and due to findings of differences in genotype between racial groups we performed further 
exploratory analyses to evaluate allele and genotype frequencies among racial subgroups with 
allergic and non-allergic asthma (Table 3).  Similar to the findings among the entire cohort, the 
HNMT-1639 (rs6430764) TT genotype was more frequent among African Americans with 
allergic asthma than non-allergic asthma (TT=0.24 allergic asthma vs.TT=0 non-allergic asthma, 





Table 3: Comparison of genotype frequencies among allergic and non-allergic asthma within 
stratified Caucasian and African American cohorts 
  
  African American  Caucasian  
SNP Genotype Allergic 
Asthma 
Subjects 




















HDC 92  
rs17740607 
CC 2(1) 0 ** 0 8(2)  0.64 
CT 0 0 25(5) 24(6) 
TT 97(41) 100(19) 75(5) 68(17) 
HRH1 -17  
rs901865 
CC 48(20) 74(14) 0.12 75(15) 72(18)  1.0   
CT 40(17) 26(5) 25(5) 28(7) 
TT 12(5) 0 0 0 
HRH4 413  
rs11665085 
CC 95(40) 95(18) 1.0 85(17) 88(22) 1.0 
CT 4(2) 5(1) 15(3) 12(3) 




CC 26(11) 26(5) 0.04 10(2) 16(4) 0.21 
CT 50(21) 74(14) 45(9) 64(16) 
TT 24(10) 0 45(9) 20(5) 
HNMT -464  
rs2071048 
CC 10(4) 11(2) 0.13 10(2) 16(4)  0.21 
CT 38(16) 63(12) 45(9) 64(16) 
TT 52(22) 26(5) 45(9) 20(5) 
HNMT 314  
rs11558538 
CC 97(41) 100(19) ** 80(16) 68(17)  0.73 
CT 2(1) 0 15(3) 28(7) 




AA 67(28) 58(11) 0.44 65(13) 48(12)  0.11 
AT 28(12) 42(8) 20(4) 48(12) 
TT 5(2) 0 15(3) 4(1) 
ABP1 47  
rs10156191 
CC 12(5) 37(7) 0.08 50(10) 36(9)  0.19 
CT 67(28) 53(10) 30(6) 56(14) 
TT 21(9) 10(2) 20(4) 8(2) 
ABP1 995  
rs1049742 
CC 81(34) 84(16) 0.30 75(15) 88(22)  0.43 
CT 19(8) 11(2) 25(5) 12(3) 
TT 0 5(1) 0 0 
ABP1 4107  
rs1049793 
CC 24(10) 26(5) 1.0 30(6) 52(13) 0.17 
CG 50(21) 47(9) 60(12) 32(8) 
GG 26(11) 26(5) 10(2) 16(4) 
*P-values represent Fishers Exact p-value for comparison of genotype frequency among Allergic 
and non-allergic asthma for African Americans and Caucasians respectively using a co-dominant 
genotype model 






Histamine related genes may be important in the pathogenesis of asthma. We observed an 
association between genetic variation within HNMT and the allergic asthma phenotype in our 
cohort of children whereby the HNMT TT genotype was associated with allergic asthma. The 
same genotype was also associated with allergic asthma among African American children.  We 
further identified an HNMT  haplotype, which includes the -1639 SNP, that was associated with 
asthma phenotype.  Our results warrant further investigation into the role of histamine related 
genes among those with allergic asthma.    
Previous investigations among varying sample sizes have yielded mixed results regarding the 
relationship between histamine related genes and asthma [34-38, 40-43, 48].  We believe that our 
study underscores the importance of conducting asthma related genetic studies within cohorts of 
well-defined asthma phenotypes and among diverse racial and ethnic groups.  African 
Americans, who bear significant morbidity and mortality associated with asthma, are a 
particularly under studied racial group among genetic studies of asthma [49]. Previous studies of 
histamine pathway genes have included very low numbers of African Americans or none at all 
[34-38, 40-43, 48].  It is essential that relationships between genetics and disease are identified 
among diverse populations so as to provide medical knowledge which will lead to improved 
diagnostic and therapeutic treatments among various racial and ethnic groups.       
 HNMT, located on chromosome 2q22, has been the most widely investigated gene, in relation to 
asthma and allergic disease, among the histamine related genes. One particular SNP, HNMT 314 
C/T, resulting in a change in amino acid (Ala138Val) and protein configuration, has been 
extensively studied.  This particular SNP has been shown to result in decreased HNMT activity 




therefore, affect pathophysiology among diseases that involve histamine. Several studies have 
been conducted to determine the potential clinical impact of this variant among those with 
allergic disease, asthma, and atopic dermatitis. A study conducted by MJ Kennedy et al., 
revealed that the HNMT 314 T variant allele was associated with atopic dermatitis among 
children [39]. Another study conducted among a cohort of predominately Caucasian adults 
observed an association between HNMT 314T variant allele and asthma [34].  Furthermore, a 
study performed by Szczepankiewicz, et al, found that the homozygous variant genotype (TT) 
for HNMT 314 occurred more frequently among Caucasian asthmatic children when compared to 
healthy controls[43].  Conflicting reports exist among various ethnic groups and asthma 
phenotypes in relation to the HNMT 314 SNP and asthma [36, 37, 40, 41].  Sasaki, et al.  also did 
not find a relationship between the SNP and allergic asthma in the Japanese cohort[40].  We also 
did not observe and association between the HNMT 314 variant and asthma among our cohort 
which is likely due to differences in linkage disequilibrium associated with differing racial 
groups. 
We observed two novel associations between HNMT SNPs, HNMT-464 and HNMT-1639, and 
allergic asthma. The HNMT-1639 SNP was also specifically relevant within the African 
American cohort in relation to asthma phenotype. Although the  functional relevance of these 
non-coding SNPs is currently unclear, our findings suggest that further investigations should 
include these variants as they may be in linkage with SNPs that result in protein changes or, 
given their position relative to the HNMT gene, may affect levels of expression. Furthermore, we 
observed an association between an HNMT haplotype that consists of wild type alleles and non-
allergic asthma which supports our findings related to individual gene variants and the allergic 




may lead to conflicting results among studies. Future studies should also include haplotype 
investigations among the histamine related genes to more clearly elucidate the role of these genes 
in disease.     
ABP1, located on chromosome 7q 34-36, encodes for DAO. Potentially functionally relevant 
SNPs have been identified for this gene. Two ABP1 SNPs, ABP1 4107C/G and ABP1 47C/T 
have been previously associated with altered DAO enzyme activity [5, 35].  In addition, Maintz, 
et al. observed that the ABP1 47 T allele was associated with “histamine intolerance”, defined as 
headache and flushing when consuming histamine-rich substances.  These findings suggest that 
variants within ABP1 may be related to the function of diamine oxidase activity which may be 
clinically important in disease phenotypes that involve histamine (e.g. allergic asthma). Previous 
literature has not reported an association between ABP1 genetic variation and asthma [20,21]. 
Garcia-Martin, et al. reported an association between ABP1 4107C/G (His645Asp) and allergic 
asthma and/or allergic rhinitis among 270 Caucasians and 295 unrelated controls [37]. The 
allergic phenotype in their study was well-defined by clinical history and environmental allergy 
skin prick testing.   Garcia-Martin did not identify an association between ABP1 4107C/G and 
asthma or allergic disease.   
Previous studies have also investigated the potential relationship between SNPs within HDC, 
which is located on located on chromosome 15q21-q22, and asthma/allergic disease.  HDC 
mRNA expression was increased in the nasal mucosa of Japanese patients with allergic rhinitis 
compared to those without the disease [17].   A study by Gervasini, et a.l, which included HDC 
nonsynonymous SNPs, (HDC 1932 A/C (Glu644Asp, rs2073440) and HDC 92C/T (Thr31Met, 




a well-defined allergic phenotype population of Caucasian subjects from Spain. They identified 
an association between HDC 1932 A/C polymorphism and allergic rhinitis alone and allergic 
rhinitis with asthma. Similar to our findings, they did not find an association between asthma 
and/or allergic disease and the HDC 92 C/T SNP.   In our study, we conducted a limited 
investigation of the gene in relation to asthma phenotype as we were limited by our smaller 
sample size. Future studies should include additional HDC SNPs so as to more clearly elucidate 
the role of the histamine related genes in asthma.    
The four genes encoding the histamine receptors, HRH1, HRH2, HRH3, and HRH4, are located 
on 3p25, 5q35.2, 20q13.33, and 18q11.2, respectively, and their relationship to asthma and 
allergic disease have been previously investigated [6]. Similar to our findings Sasaki did not find 
an association between SNPs within the histamine receptor genes and allergic asthma among 
Japanese participants.  Others have also investigated HRH4 and its potential association with 
asthma and allergic disease. In our study we did not observe differences in allele or genotype 
frequency between the allergic and non-allergic asthmatics for HRH4 413C/T.  In a previous 
study, conducted in Caucasian children of Hungarian decent, investigators looked at 21 SNPs, 
including HRH4 413 C/T, in relation to various asthma phenotypes (e.g. allergic asthma, exercise 
induced asthma).  In their study, where allergic asthma was defined by environmental allergy 
skin prick testing, they also did not find an association between the HRH4 413C/T SNP and the 
disease [42].   However, they did identify an association between other variants, which were not 
included in our study (HRH4 rs527790, rs487202, rs17187619) and “infection-induced asthma”. 
Of the HRH4 nonsynonymous SNPs currently identified, none are reported to be observed 
consistently at high frequency among African Americans [6]. Therefore, this gene may be of less 




within our group. Yu, et al. also investigated HRH4 genetic variants and found an association 
with 3 different SNPs (rs77485247, rs74604924, rs77041280) and atopic dermatitis. More recent 
data from the same group also suggests that amplification of the HRH4 copy number is also 
associated with atopic dermatitis [50].  As the HR4 receptor has been most extensively 
associated with pruritus, their findings are biologically plausible and deserve more investigation 
[51, 52]. Perhaps HRH4 is most important in the pathogenesis of atopic dermatitis and may not 
be as influential in the pathogenesis of asthma.   
The most significant limitation of our study was the small sample size and further limited sample 
size for analyses conducted among racial groups.  We may not have been able to detect small 
differences in gene frequency between the allergic and non-allergic groups. However, the 
differences that we did observe are not likely due to chance given the large difference required 
for detection in a small sample size. Racial heterogeneity among our cohort is a limitation and 
further studies should focus on larger racially homogeneous populations given known 
differences in inheritance and linkage disequilibrium between racial groups. We believe that our 
findings among the African American participants deserve more investigation given the large 
differences in genotype frequency observed between the allergic and non-allergic groups in this 
racial group. It is likely that the differences in genotype observed among the entire cohort for 
HNMT1639 were most likely driven by the African American racial group.  We also recognize 
that SNPs identified to be associated with allergic asthma are in non-coding regions and 
therefore may only be “tagging” SNPs. Further work is needed to determine the potential 
functional significance of these SNPs and to identify other more functionally relevant SNPs that 




We believe that our findings are important in further understanding the pathophysiology of 
asthma among different patient populations.  With validation, this information may be useful in 
utilizing genotype in predicting therapeutic response to antihistamines for the treatment of 
asthma. As those with altered histamine production or degradation or receptor function may 
respond differently to antihistamines.   Future studies are needed to confirm our results in a 
larger cohort of participants with allergic asthma, specifically focusing on potentially relevant 
and understudied subgroups (e.g. African American).  In addition, further studies are required to 
determine the functional significance of identified SNPs and their impact on disease phenotype 
as well as inclusion of other potentially important histamine related genes (HRH2, HRH3) and 
haplotypes.  Our study supports re-visiting the role of histamine in asthma and the role of 
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